Alimera Sciences takes legal action against ANI Pharmaceuticals to enforce merger agreement

Alimera Sciences has filed a lawsuit in the Delaware Court of Chancery to compel ANI Pharmaceuticals to fulfill its contractual obligation to close the transaction contemplated by the companies’ previously announced agreement and plan of merger dated June 21, following Alimera shareholders’ approval of the transaction on Sept. 4.

Alimera issued the following statement:

“Alimera has fulfilled all its requirements to close the Merger Agreement, yet ANI has failed to adhere to its obligation to close on time. We believe the merger offers compelling value for our shareholders and remain focused on completing the transaction. Accordingly, we are committed to taking all actions necessary to ensure that happens. We are confident we will prevail in the Delaware Court of Chancery and look forward to consummating the merger of our companies.”

[Read more: ANI debuts generic Fleqsuvy]

Specifically, Alimera’s lawsuit asks the Court to require ANI to comply with its obligations to complete the transaction as contemplated by the merger agreement.

[Read more: ANI obtains FDA OK for generic Divigel]